Superbug outbreak in ICU during COVID: lessons learned
NCT ID NCT05055479
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks back at an outbreak of a hard-to-treat bacteria (VIM-producing Enterobacter cloacae) in an intensive care unit during the 2020 COVID-19 pandemic. Researchers reviewed the cases of 14 ICU patients who had this superbug to understand how the hospital managed the outbreak. The goal was to show what steps worked to stop the spread, not to test a new treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ENTEROBACTERIACEAE INFECTIONS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CHU Amiens Picardie
Amiens, Picardie, 80054, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Probiotics join the fight against superbugs in the gut
- Superbug sleuths decode the DNA of drug-resistant e. coli to stop its spread
- Could a common antibiotic spare Last-Resort drugs for ICU lung infections?
- Poop pills vs. superbugs: can a fecal transplant beat resistant gut bacteria?
- Pain clinic study reveals hidden infection dangers in epidural devices
- Superbug sleuths: DNA detectives hunt hospital infection sources